Sight Sciences, Inc. (SGHT) company profile
Close on Nov 18, 2026Market cap $593.30MP/E –Yield –
About Sight Sciences
Surgical & Medical Instruments & Apparatus, SIC 3841
Sight Sciences, Inc. is an ophthalmic medical device company that develops surgical and therapeutic technologies for eye conditions, primarily glaucoma and dry eye disease. The company operates in two segments: Interventional Glaucoma and Interventional Dry Eye. In the Interventional Glaucoma segment, it offers the OMNI Surgical System to reduce intraocular pressure in adults with primary open-angle glaucoma, and the SION Surgical Instrument to excise trabecular meshwork tissue. In the Interventional Dry Eye segment, it offers the TearCare system, which applies localized heat to clear meibomian gland obstructions. Its customers are eyecare professionals, including ophthalmic surgeons, ophthalmologists, and optometrists.
The company maintains direct commercial operations in the United States, the United Kingdom, and Germany, and sells products in other European countries through distributors. Within the United States, it markets its products through dedicated sales forces. Sight Sciences is headquartered in Menlo Park, California.
Summary of the business section of Sight Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sight Sciences, Inc.
- Headquarters
- Menlo Park, CA
- Address
- 4040 Campbell Ave,, Suite 100 94025
- Phone
- (415) 889-0550
- Website
- sightsciences.com
- Employees
- 186, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- DELOITTE & TOUCHE LLP, San Jose, California
Stock & identifiers
- Ticker
- SGHT
- Exchange
- Nasdaq
- IPO date
- Jul 15, 2021
- Shares outstanding
- 55M, Jul 31, 2026
- Public float
- $153.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1531177
- CUSIP
- 82657M105
- ISIN
- US82657M1053
- FIGI
- BBG006BZHZC7
- Share class FIGI
- BBG006BZHZD6
- EIN
- 80-0625749
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul Badawi | President and CEO, Director | 6,092,819 |
| David Badawi | Chief Technology Officer, Director | 1,975,075 |
| Brenton Taylor | EVP, Operations & R&D | 261,990 |
| Alison Bauerlein | Chief Operating Officer | 639,449 |
| James Rodberg | Chief Financial Officer | 216,829 |
| Kashif Rashid | Chief Legal Officer | 181,818 |
| Jeremy B. Hayden | Chief Legal Officer | 357,037 |
| Manohar K. Raheja | EVP, Research & Development | 167,767 |
| Matthew Link | Chief Commercial Officer | 832,293 |
| Staffan Encrantz | Director | 6,521,203 |
| Gerhard F. Burbach | Director | 123,207 |
| Catherine Mazzacco | Director | 106,768 |
| Donald Zurbay | Director | 193,613 |
| Tamara Fountain | Director | 109,650 |
| Brenda Jane Larsen-Becker | Director | 79,040 |
| Erica J. Rogers | Director | 175,352 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Paul Badawi President and Chief Executive Officer | $659.00K | $1.00M | $334.61K | $12.00K | $2.01M | -34% |
| Alison Bauerlein Chief Operating Officer | $474.90K | $950.00K | $196.50K | $5.25K | $1.63M | -27% |
| Jeremy Hayden Chief Legal Officer | $433.00K | $390.00K | $146.57K | $4.68K | $974.25K | -34% |
| Matthew Link Chief Commercial Officer | $288.13K | $480.00K | – | $448.79K | $1.22M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 15, 2021
- Offer price
- $24.00
- Securities offered
- 10,000,000
- Gross proceeds
- $240.00M
- Exchange
- Nasdaq
- First trading day
- Jul 15, 2021
- First-day close
- $33.50+39.6%
- Lock-up ends (est.)
- Jan 11, 2022
“The initial public offering price of our common stock is $24 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 186 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 2, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 15, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 8, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?